Working… Menu

Mesenchymal Stem Cell Therapy in Multiple System Atrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02315027
Recruitment Status : Active, not recruiting
First Posted : December 11, 2014
Last Update Posted : February 12, 2021
Information provided by (Responsible Party):
Wolfgang Singer, Mayo Clinic

Brief Summary:
The purpose of this study is to determine whether mesenchymal stem cells (MSCs) can be safely delivered to the cerebrospinal fluid (CSF) of patients with multiple system atrophy (MSA). Funding Source - FDA OOPD.

Condition or disease Intervention/treatment Phase
MSA Biological: autologous mesenchymal stem cells Phase 1

Detailed Description:
The primary aim is to evaluate the safety and tolerability of intrathecal injection of autologous MSCs in a dose escalation study in patients with MSA. Safety secondary goals include to monitor changes in peripheral blood and in components of CSF, and monitor for any changes of nervous system structures using MRI. Efficacy secondary goals include evaluating potential efficacy by providing a number of studies and instruments that will detect changes in the course of the disease in terms of autonomic and neurologic symptoms and deficits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History
Study Start Date : October 2012
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: autologous mesenchymal stem cells
Administration of autologous mesenchymal stem cells
Biological: autologous mesenchymal stem cells

There will be three treatment groups of up to 8 patients each. Groups 1 will receive a single dose of cells. Groups 2 and 3 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:

  • Group 1: single intrathecal dose of 1 x 107 cells.
  • Group 2: one intrathecal dose of 5 x 107 cells followed one month (+/- 4 days) later by a second intrathecal dose of 5 x 107 cells.
  • Group 3: one intrathecal dose of 1 x 108 cells followed one month (+/- 4 days) later by a second intrathecal dose of 1 x 108 cells.

Primary Outcome Measures :
  1. Adverse event frequency (by severity, type, attribution, and intervention dose). [ Time Frame: 14 months ]

Secondary Outcome Measures :
  1. Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort). [ Time Frame: 12 months ]
  2. Rate of change from baseline to 12 months (or last available date) in UMSARS II score. [ Time Frame: 12 months ]
  3. Rate of change from baseline to 12 months (or last available date) in UMSARS total score. [ Time Frame: 12 months ]
  4. Rate of change in COMPASS-select score from baseline to 12 months. [ Time Frame: 12 months ]
  5. Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months. [ Time Frame: 12 months ]
  6. MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months. [ Time Frame: 12 months ]
  7. Change in CSF biomarkers from baseline to 2 months. [ Time Frame: 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Participants aged 30-80 years old with a diagnosis of MSA based on clinical criteria and standardized autonomic testing. This approach allows for identification of patients with MSA with very high specificity and is yet sensitive enough to allow for enrollment of patients at a disease stage at which an intervention on the natural disease course has a meaningful impact on patient outcome. Patients therefore have to fulfill Gilman Criteria (2000) for probable MSA of the parkinsonian subtype (MSA-P) or cerebellar subtype (MSA-C) and have findings on autonomic function testing suggestive of MSA (CASS ≥5 or a TST% ≥25%).
  2. Participants who are less than 4 years from the time of documented MSA diagnosis.
  3. Participants with an anticipated survival of at least 3 years in the opinion of the investigator.
  4. Participants who are willing and able to give informed consent.
  5. "Normal" cognition as assessed by Mini-Mental State Examination (MMSE). We will require a value >24.

Exclusion Criteria

Any of the following conditions will exclude the participant from entering the study:

  1. Women of childbearing potential who do not practice an acceptable method of birth control. Acceptable methods of birth control in this study are: surgical sterilization, intrauterine devices, partner's vasectomy, a double-protection method (condom or diaphragm with spermicide), hormonal contraceptive drug (i.e., oral contraceptive, contraceptive patch, long-acting injectable contraceptive) with a required second mode of contraception.
  2. Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the study or might affect the results of the study. These include conditions causing significant central nervous system (CNS) or autonomic dysfunction, including congestive heart failure, recent (<6 months) myocardial infarct, cardiopulmonary disease, severe, uncontrolled hypertension, thrombocytopenia (<50 x 10(9)/L), severe anemia (<8g/dl), immunocompromised state, liver or kidney disease (creatinine >2.3mg/dl), uncontrolled diabetes mellitus (HbA1c >10g%), alcoholism, amyloidosis, uncontrolled hypothyroidism, sympathectomy, unstable peripheral neuropathies, concurrent infections, orthopedic problems that compromise mobility and activity of daily living, cerebrovascular accidents, neurotoxin or neuroactive drug exposure, parkinsonism due to drugs (including neuroleptics, alpha-methyldopa, reserpine, metoclopramide).
  3. Participants with malignant neoplasms.
  4. Participants who have taken any investigational products within 60 days prior to baseline.
  5. Medications that could affect autonomic function. If patients are taking those medications, those will be suspended prior to autonomic testing. Therapy with midodrine, anticholinergic, alpha and beta adrenergic antagonists or other medications that affect autonomic function will be withdrawn 48 hours prior to autonomic evaluations. Fludrocortisone doses up to 0.2 mg per day will be permitted.
  6. Diseases with features of Parkinsons Disease; e.g., diffuse Lewy body disease, progressive supranuclear palsy, essential tremor, hereditary olivopontocerebellar atrophy, or postencephalitic parkinsonism.
  7. Dementia (DSM-IV criteria - American Psychiatric Association 1994). The score on the Mini-Mental State Examination must be >24.
  8. History of electroconvulsive therapy.
  9. History of brain surgery for Parkinsons disease.
  10. Patients with contraindication for MRI scanning, including those with MRI-incompatible pacemakers
  11. Patients with active systemic infection or local infection, which is close to the spinal injection site

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02315027

Layout table for location information
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Wolfgang Singer, MD Mayo Clinic
Principal Investigator: Phillip Low, MD Mayo Clinic
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Wolfgang Singer, Associate Professor, Mayo Clinic Identifier: NCT02315027    
Other Study ID Numbers: 12-005950
G4789 ( Other Grant/Funding Number: FDA - OOPD )
First Posted: December 11, 2014    Key Record Dates
Last Update Posted: February 12, 2021
Last Verified: February 2021
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple System Atrophy
Shy-Drager Syndrome
Pathological Conditions, Anatomical
Primary Dysautonomias
Autonomic Nervous System Diseases
Nervous System Diseases
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Vascular Diseases
Cardiovascular Diseases